Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program

Autor: Bruno, S, Bollani, S., Zignego, A. L., Pascasio, J. M., Magni, C., Ciancio, A., Caremani, M., Mangia, A., Marenco, S., Piovesan, S., Chemello, L., Babudieri, S., Moretti, A., Gea, F., Colletta, C., Perez Alvarez, R., Forns, X., Larrubia, J. R., Arenas, J., Crespo, J., Calvaruso, V., Ceccherini Silberstein, F., Maisonneuve, P., Craxì, A., Calleja, J. L., Di Marco, V., Monti, M., Rizzardini, G., Landonio, S., Rizzetto, M., Lapini, L. E., Piazzolla, V., Picciotto, A., Alberti, A., Cavaletto, L., Koch, M., Massari, M., Muratori, L., Cipriano, V., Montineri, A., Iacobello, C., Fangazio, S., Pirisi, M., Colombo, A., Bellati, G., Mazzotta, F., Pierotti, P., Traverso, A., Serviddio, G., Russello, M., Santantonio, T., Drenaggi, D., Marchionne, E., Zuin, M., Delliponti, M., Farina, F., Andreone, P., Scuteri, A., Galli, M., Giannini, EDOARDO GIOVANNI, Nerli, A., Carbonai, S., Coppola, N., Montalbano, M., Portelli, V., Di Biagio, A., Nicolini, LAURA AMBRA, Mastroianni, C., Madonia, S., Licata, A., Montalto, G., Giannitrapani, L., Mondelli, M., Pellicelli, A., Toniutto, P., Borgia, G., Gentile, I., De Luca, M., Di Costanzo, G. G., Corti, G., Sousa, M., Delgado, M. B., De La Revilla, J., Navarro, J. M., Barcena, R., Romero Gomez, M., Fernandez Rodriguez, C. M., Narvaez, I., Erdozain, J. C., Molina, E., Fernandez, I., Cuenca, B., Planas, R., Garcia Samaniego, J., Ladero, J. M., Gonzalez, J. M., Serra, M. A., Castellote, I., Sola, R., Anton, T., Ryan, I., Gonzalez, F., Martinez, E., Portu, J.

In many countries, first-generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV-infected patients. Subjects with advanced disease and previous failure to P/R urgently need therapy, but the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55eee2a0c597fb9dbf1b0b00fe79cea9
http://hdl.handle.net/11390/1190517

Oscillations in serum ferritin associated with antiviral therapy in chronic hepatitis C

Autor: Ladero, J. M., López-Alonso, G., Devesa, M. J., Cuenca, F., Ortega, L., Agreda, M., Suárez, A., Ropero, P., Díaz-Rubio, M.

Publikováno v: Revista Española de Enfermedades Digestivas, Volume: 101, Issue: 1, Pages: 31-40, Published: JAN 2009

Background: hyperferritinemia is often found in patients with chronic hepatitis C (CHC) and is predictive of poorer response to antiviral therapy. Objective: to investigate changes in ferritinemia during and after antiviral therapy. Patients and meth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______624::fd2b9f97e0f79239082c9095562650fd
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082009000100004&lng=en&tlng=en

La mutacion H63D del gen HFE se asocia con un riesgo aumentado de carcinoma hepatocelular

Autor: Ropero, P., Briceno, Olga, Lopez-Alonso, G., Agundez, J. A. G., Fernandez, F. A. Gonzalez, Garcia-Hoz, F., Martinez, Villegas, Dfaz-Rubio, M., Ladero, J. M.

Publikováno v: Revista Española de Enfermedades Digestivas, Volume: 99, Issue: 7, Pages: 376-381, Published: JUL 2007
Publons

Objetivo: comprobar si las mutaciones del gen HFE, que pueden inducir sobrecarga hepática de hierro, guardan relación con el riesgo de desarrollar carcinoma hepatocelular (CHC) en sujetos predispuestos a sufrir este tumor. Material y métodos: se h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c971eee96efc98ab2dd05965bfa2d307
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082007000700002&lng=en&tlng=en

Hereditary hyperferritinemia-cataract syndrome: Study of a new family in Spain

Autor: Ladero, J. M., Balas, A., García-Sánchez, F., Vicario, J. L., Díaz-Rubio, M.

Publikováno v: Revista Española de Enfermedades Digestivas, Volume: 96, Issue: 7, Pages: 507-511, Published: JUL 2004

The hyperferritinemia-cataract syndrome, inherited as a Mendelian dominant trait, is due to mutations in the 5’ non-coding region of the ferritin light chain gene that modifies the shape of the IRE (iron responsive element) region, which loses its

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______624::5b7025de138228e4f4b31c8182a67c57
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082004000700008&lng=en&tlng=en

CYP2D6 polymorphism is not associated with essential tremor

Autor: José Agundez, Jiménez-Jiménez, F. J., Tejeda, R., Ledesma, M. C., Ortí-Pareja, M., Gasalla, T., Molina, J. A., Ruiz, J., Coria, F., Duarte, J., Vázquez, A., Ladero, J. M., Benítez, J.

Publikováno v: Europe PubMed Central
Scopus-Elsevier

Recent reports have shown an association between cytochrome P450IID6 (CYP2D6) polymorphism and Parkinson's disease. We investigated the association between this polymorphism and the risk for developing essential tremor (ET). Leukocytic DNA from 91 un

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::13d94f97c34b8ec2ae7d61a3cef6c47b
https://pubmed.ncbi.nlm.nih.gov/9286632